All three tenses have at least two readings, so the archetype blend applies as printed.
Of the nine metrics, 8 read as filed from the record and 1 is an SI estimate, each with its reasoning, its confidence and what would change it on its card.
What did they actually do?
Has it survived what it has been through?
7 warning events since 2017; the latest 2026-09-04.
From the record
Arcadia Biosciences, Inc.'s filings since 2017 show 7 warning events of 2 kinds: a notice about its exchange listing (8-K item 3.01, 6 times, the latest 2026-09-04); an auditor change (8-K item 4.01, the latest 2026-04-03) (its current reports).
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What has it actually done, year after year?
+2.4% a year over 9 filed years; profitable in 0 of 9.
From the record
Arcadia Biosciences, Inc.'s 9 filed years say what it did: revenue went from $4 million in fiscal 2017 to $5 million in fiscal 2025, up 2.4% a year; it rose in 3 of 8 years; the deepest fall was 71% from fiscal 2017 to fiscal 2019; net income was positive in 0 of 9 of those years (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How has it treated the people who own it?
SI estimate 1.1/10, confidence 35 of 100 (one part).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: Arcadia Biosciences, Inc.'s shareholder treatment is put at 1.1 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the bottom 11% of 78 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.
What are they doing right now?
Is it financially healthy right now?
ROE -56%: lost 56¢ per shareholder dollar. Leverage 37%: owes 37¢ per asset dollar.
From the record
Return on equity: in the fiscal year ended 2025-12-31, Arcadia Biosciences, Inc. lost about 56 cents for every dollar of shareholders' money, and gross profitability: its products earned about 27 cents per dollar of everything the company owns (revenue less the cost of revenue). Leverage: it owed about 37 cents per dollar of assets, and net share issuance: its share count grew 0.3% over the year (the filed statements).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How strong is its position in its industry?
bottom 14% of 76 in its family; net margin -48.1%.
From the record
Arcadia Biosciences, Inc.'s standing among 76 graded names in its industry family: revenue of $5 million in fiscal 2025 ranks in the bottom 8% by size; a net margin of -48.1% ranks in the bottom 11%; revenue growth of -13.2% a year over the last 3 filed years ranks in the bottom 23% (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are the people in charge doing?
bottom 46% of 51 in its family for leadership.
From the record
Arcadia Biosciences, Inc.'s leadership, from its insiders' filings and its current reports: no one files under a chief executive's title, so that part is not read; the 4 officers and directors filing in the last fifteen months have been on the record a median of 9.3 years (top 8%); 9 officer or director changes were reported on Form 8-K since 2023-11-13, against the 4 people in charge now (bottom 1%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are they set up to do next?
How much room does it have to grow?
bottom 28% of 74 in its family for room to expand.
From the record
Arcadia Biosciences, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $259 thousand against no long-term debt tagged leaves 4% of its assets as net cash, top 19% of its family; cash from operations less capital spending is -97.6% of revenue (bottom 6%); a gross margin of 36.2% (bottom 21%); research spending of 0.2% of revenue (bottom 6%) (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What could actually drive growth from here?
bottom 35% of 72 in its family for growth drivers.
From the record
Arcadia Biosciences, Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew -13.2% a year over the last three filed years against 2.4% over all 9, slowing (top 47% of its family); the newest year grew -3.7% (bottom 46%); research spending grew -81.9% a year (bottom 5%) (its annual reports). Arcadia Biosciences, Inc. tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
Did its newest year beat what its own record pointed to?
top 17% of 69 in its family for expectations against reality.
From the record
Arcadia Biosciences, Inc.'s newest year against its own record: revenue of $5 million in fiscal 2025 came in 16.7% above the $4 million its prior three years' pace pointed to (top 38% of its family); net income of $2 million against a prior three-year average of $12 million (top 11%); a net margin of -48.1% against losses larger than its revenue before (top 2%) (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made